PLoS One 2024;19:e0306296
Comparing Semaglutide to Tirzepatide for Abdominal Fat Loss Tirzepatide (a GLP-1/GIP dual agonist) shows slightly faster visceral fat reduction than semaglutide alone in head-to-head studies because it activates two appetite-control pathways instead of one
It is composed of just six amino acids
Sublingual Semaglutide Compounds Dosing, Clinical Application & Regulatory
457,458 Biomacromolecular approaches, including those involving proteins, oligonucleotides, and antibodies, play pivotal roles in the treatment of metabolic diseases
Whilst GLP-1 receptors are indeed present in various brain regions, including areas involved in mood regulation such as the hippocampus and hypothalamus, their activation by semaglutide does not translate to direct serotonin modulation